Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 16, 2020 01:00 ET | Source: F. Hoffmann-La Roche Ltd

Roche ranked the most sustainable healthcare company in the Dow Jones Sustainability Indices for the eleventh time

The ranking acknowledges Roche’s commitment to sustainability as an integral part of its business strategy Roche performed particularly well in Marketing Practices, Environmental and Social Reporting,...
November 13, 2020 11:00 ET | Source: F. Hoffmann-La Roche Ltd

CHMP recommends EU approval of Roche’s Xofluza® (baloxavir marboxil) for the treatment of influenza

One-dose, oral Xofluza has been recommended for approval for the treatment of uncomplicated influenza in patients aged 12 years and aboveXofluza has also been recommended for approval as a preventive...
November 13, 2020 08:00 ET | Source: F. Hoffmann-La Roche Ltd

CHMP recommends EU approval of Roche’s Phesgo (fixed-dose combination of Perjeta and Herceptin for subcutaneous injection) for HER2-positive breast cancer

Phesgo offers faster and less invasive delivery of standard of care treatment with Perjeta and Herceptin, under the skin in just minutes, compared to hours with intravenous infusion1,2,3Subcutaneous...
November 05, 2020 09:00 ET | Source: F. Hoffmann-La Roche Ltd

Roche to present new data across 16 blood disorders at the American Society of Hematology 2020 Annual Meeting

New data for Roche’s CD20xCD3 bispecific antibodies will be featured, as well as first clinical data on cevostamab, a first-of-its-kind FcRH5xCD3 bispecific antibody, in multiple myelomaLonger-term...
November 02, 2020 01:00 ET | Source: F. Hoffmann-La Roche Ltd

European Commission approves Roche’s Tecentriq in combination with Avastin for the treatment of people with the most common form of liver cancer

Tecentriq in combination with Avastin is the first and only cancer immunotherapy regimen approved in Europe for the treatment of unresectable hepatocellular carcinoma (HCC), the most common form of...
October 29, 2020 02:00 ET | Source: F. Hoffmann-La Roche Ltd

Roche’s Tecentriq in combination with Avastin approved in China for people with the most common form of liver cancer

Tecentriq in combination with Avastin is the first and only cancer immunotherapy regimen approved for the treatment of unresectable hepatocellular carcinoma (HCC), the most common form of liver cancer...
October 22, 2020 01:00 ET | Source: F. Hoffmann-La Roche Ltd

Roche announces collaboration with Atea Pharmaceuticals to develop a potential oral treatment for COVID-19 patients

Roche and Atea partner to jointly develop AT-527, an orally administered direct-acting antiviral (DAA) currently in Phase 2 clinical trialsAT-527 has the potential to be the first novel oral antiviral...
October 19, 2020 01:00 ET | Source: F. Hoffmann-La Roche Ltd

Roche announces full FDA approval for Venclexta combinations for acute myeloid leukaemia

Approval supported by data from phase III confirmatory trials, VIALE-A and VIALE-C VIALE-A study showed Venclexta plus azacitidine significantly improved overall survival in newly diagnosed AML...
October 15, 2020 01:00 ET | Source: F. Hoffmann-La Roche Ltd

First nine months of the year with 1% sales growth at constant exchange rates, significant impact of COVID-19 pandemic

Group sales increase 1%1 at constant exchange rates and decline 5% in Swiss francs as a result of continued appreciation of the Swiss franc against most currencies Impact of COVID-19 pandemic:...
October 15, 2020 01:00 ET | Source: F. Hoffmann-La Roche Ltd

Les neuf premiers mois de l’exercice marqués par une croissance de 1% à taux de change constants et par l’impact significatif de la pandémie de COVID-19

Le chiffre d’affaires consolidé s’inscrit en hausse de 1%1 à taux de change constants et en repli de 5% en francs suisses, en raison de l’appréciation continue du franc suisse par rapport à la plupart...